Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 9,600 Shares

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total value of $300,000.00. Following the completion of the transaction, the chief financial officer owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. The trade was a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Friday, March 13th, Christine Mikail Cvijic sold 4,045 shares of Neurogene stock. The stock was sold at an average price of $20.81, for a total value of $84,176.45.

Neurogene Price Performance

Shares of NGNE stock traded down $0.46 on Friday, reaching $30.80. 93,184 shares of the stock were exchanged, compared to its average volume of 167,429. The stock has a market cap of $481.05 million, a PE ratio of -7.28 and a beta of 1.69. Neurogene Inc. has a one year low of $13.69 and a one year high of $37.27. The stock has a 50 day moving average price of $23.04 and a 200 day moving average price of $22.07.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.08. On average, research analysts expect that Neurogene Inc. will post -5.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NGNE has been the subject of a number of recent analyst reports. Canaccord Genuity Group dropped their price objective on Neurogene to $180.00 and set a “buy” rating for the company in a report on Monday, April 6th. Lifesci Capital began coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price for the company. Guggenheim began coverage on Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Jennison Associates LLC boosted its position in shares of Neurogene by 35.3% during the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after buying an additional 138,999 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Neurogene during the fourth quarter valued at approximately $575,000. Los Angeles Capital Management LLC acquired a new position in Neurogene during the fourth quarter valued at approximately $299,000. Renaissance Technologies LLC acquired a new position in Neurogene during the fourth quarter valued at approximately $288,000. Finally, Alps Advisors Inc. bought a new stake in Neurogene in the fourth quarter valued at approximately $262,000. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.